\
&
Contact us
\
&
Contact us
Biodiversa+ is the European Biodiversity Partnership that supports excellent research on biodiversity with an impact on policy and society. Biodiversa+ is working towards the 2050 vision of “living in harmony with nature,” in line with global biodiversity goals and the EU Biodiversity Strategy for 2030.
The partnership aims to halt ecosystem loss by 2030, reduce species extinction risks, and support the recovery of biodiversity across Europe.
A major focus is on scaling up nature-based solutions to address societal challenges while strengthening the role of biodiversity in sustainable development and the green economy.
To deliver impact, Biodiversa+ has identified five strategic objectives, including improving biodiversity monitoring, generating actionable knowledge, and supporting evidence-based policymaking. It also promotes science-based approaches to valuing ecosystem services and natural capital, helping integrate biodiversity into broader decision-making.
These ambitions are implemented through nine interconnected work packages covering research and innovation, monitoring, policy support, international cooperation, and stakeholder engagement. Communication, open science, and coordination are also central to ensuring that Biodiversa+ activities remain aligned and effective.
Together, these efforts are designed to drive transformative change and put biodiversity on a path to recovery in Europe and beyond.
Contact
Partners: BiodivERsA / FRB - Claire Blery
Belgian Science Policy Office (BELSPO) Aline van der Werf
FWO: Toon Monbaillu
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
pascal.verheye@vlaio.be
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
